Public Notice on the Selection Results of the Sub-Funds of Nanjing Biomedical Industry Master Fund
On August 18, 2025, Nanjing Zijing Biomedical Industry Investment Fund Partnership (Limited Partnership) (referred to as the "Nanjing Biomedical Industry Master Fund") held the 1st meeting of its Sub-Fund Investment Decision-Making Committee, at which the sub-funds to be equity-participated in by the Nanjing Biomedical Industry Master Fund were reviewed and approved. Details are as follows:
Nanjing Enran Chengfeng Venture Capital Partnership (Limited Partnership)
The fund has a target scale of RMB 314.37 million, is registered and based in Jiangbei New Area of Nanjing, with a term of 8 years. It will mainly invest in fields related to biomedicine and medical health.
In accordance with the requirements specified in the Announcement on the Selection of Managers for Proposed Sub-Funds of the Nanjing Biomedical Industry Master Fund, after going through processes including institutional application, preliminary review of materials, due diligence, and investment decision-making, the proposed sub-funds to be equity-participated in (attached below) are now publicly announced. The public announcement period is 5 working days, from August 20, 2025 to August 26, 2025.
Any entity or individual with objections to the announced results shall submit them in writing during the public announcement period, and list the reasons for the objections and relevant supporting materials. If the objection is submitted in the name of an entity, the official seal of the entity shall be affixed to the objection materials; if submitted in the name of an individual, the individual’s real name, affiliated unit, contact address, and contact information shall be clearly stated, and the individual shall sign the objection materials. To ensure that the handling of objections is objective, fair, impartial, and timely, any anonymous objections or objections submitted beyond the public announcement period will not be accepted.
Contact Person: Ms. Wang
Contact Phone: 025-86596530
Contact Email: selection@njicg.com
Contact Address: 41F, Building 4, Financial City, Jianye District, Nanjing, Jiangsu Province
Attachment: List of Proposed Sub-Funds to Be Equity-Participated in by the Nanjing Biomedical Industry Master Fund
Source: Venture Capital Group
Review: Xue Yao
Release: You Yi
